Stealth BioTherapeutics Operating Income

Stealth BioTherapeutics (MITO) currently reports a operating income of $-48M as of March 2022. That compares with $-45M in the prior-year period — down 8.0% year over year. Use the charts on this page to explore Stealth BioTherapeutics's operating income history and peer comparisons.

Stealth BioTherapeutics's operating income decreased from $-45M to $-48M — a 8.0% year-over-year decrease (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Stealth BioTherapeutics reported $-48M in operating income as of March 2022. That compares with $-45M in the prior-year period — down 8.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-48M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Stealth BioTherapeutics, and consider following MITO for alerts when major investors trade the stock.

Stealth BioTherapeutics is classified in the Healthcare sector. On operating income, it currently shows $-48M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MITO with unrelated industries.